• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by OraSure Technologies, Inc.

    11/8/21 8:05:29 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care
    Get the next $OSUR alert in real time by email
    SC 13D 1 OSUR13D.htm PRIMARY DOCUMENT  
     
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13D
     
    Under the Securities Exchange Act of 1934
     
     
    ORASURE TECHNOLOGIES, INC
    (Name of Issuer)
     
     
    Common stock, $0.000001 par value
    (Title of Class of Securities)
     
    68554V108
    (CUSIP Number)
     
    Camber Capital Management LP, 101 Huntington Avenue, Suite 2101, Boston, MA 02199
    617-717-6600
    (Name, Address and Telephone Number of Person Authorized to
    Receive Notices and Communications)
     
     
    November 08, 2021
    (Date of Event which Requires Filing of this Statement)
     
    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ⌧
     
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
     
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     
     
     
     
    1.  Names of Reporting Persons.
    Camber Capital Management LP
    42-1693587
     
    2.  Check the Appropriate Box if a Member of a Group
    (a) ☐
    (b) X
     
    3.  SEC Use Only
    4.  Source of Funds
         WC
    5.  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
    ☐
    6.  Citizenship or Place of Organization
         Camber Capital Management LP - Delaware
     
     
       Number of Shares
       Beneficially
       Owned by
       Each Reporting
       Person With:
     
     
    7.  Sole Voting Power
         0 shares  
     
    8.  Shared Voting Power
         4,250,000 shares
     
    9.  Sole Dispositive Power
         0 shares  
     
    10.  Shared Dispositive Power
           4,250,000 shares
     
    11.  Aggregate Amount Beneficially Owned by Each Reporting Person
            4,250,000 shares
    12.  Check if the Aggregate Amount in Row (11) Excludes Certain Shares
    ☐
    13.  Percent of Class Represented by Amount in Row (11)
           5.90%
    14.  Type of Reporting Person
           IA
     
     
     
     
    1.  Names of Reporting Persons.
         Stephen DuBois
     
    2.  Check the Appropriate Box if a Member of a Group
    (a) ☐
    (b) X
     
    3.  SEC Use Only
    4.  Source of Funds
         WC
    5.  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
    ☐
    6.  Citizenship or Place of Organization
         Stephen DuBois - Massachusetts
     
     
       Number of Shares
       Beneficially
       Owned by
       Each Reporting
       Person With:
     
     
    7.  Sole Voting Power
         0 shares
     
    8.  Shared Voting Power
          4,250,000 shares
     
    9.  Sole Dispositive Power
         0 shares
     
    10.  Shared Dispositive Power
          4,250,000 shares
     
    11.  Aggregate Amount Beneficially Owned by Each Reporting Person
           4,250,000 shares
    12.  Check if the Aggregate Amount in Row (11) Excludes Certain Shares
    ☐
    13.  Percent of Class Represented by Amount in Row (11)
           5.90%
    14.  Type of Reporting Person
            IN, HC
     
     
     
     
     
    ITEM 1. SECURITY AND ISSUER
     
    This statement on Schedule 13D refers to the shares of common stock, par value $0.000001 per common stock (the "Shares"), of ORASURE TECHNOLOGIES, INC. (the "Company"). The Company's principal executive office is located at 220 East First Street, Bethlehem, Pennsylvania 18015
     
    ITEM 2. IDENTITY AND BACKGROUND
     
     
    (a)
    Camber Capital Management LP, a Delaware limited partnership ("Camber"), which serves as the investment manager of two private investment funds that beneficially own the Shares reported herein. Stephen DuBois ("Mr. DuBois") serves as managing member of Camber. In such capacities, Camber and Mr. DuBois (the "Reporting Persons") beneficially own the Shares reported herein.
     
     

     
    (b)
    The principal business address of each of the Reporting Persons is 101 Huntington Avenue, Suite 2101, Boston, Massachusetts 02199-8089.
     
     
    (c)
    The principal business of Camber is to invest in securities. The principal business of Mr. DuBois is the management of investments in securities.
     
     
    (d)
    None of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
     
     
    (e)
    None of the Reporting Persons has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
     
     
    (f)
    Camber is a limited partnership organized under the laws of the State of Delaware. Mr. DuBois is a citizen of the United States.
     
     
     
     
    ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
     
    The 4,250,000 Shares to which this Schedule 13D relates were acquired for an aggregate purchase price of $49,106,256 (an average of $11.55 per Share) using working capital of the private investment funds referred to above.
     
    ITEM 4. PURPOSE OF TRANSACTION
     
    The Shares to which this Schedule 13D relates were acquired based on the Reporting Persons’ belief that such Shares represent an attractive investment opportunity.
    The Reporting Persons believe the current trading value of the Shares does not reflect their intrinsic value. Accordingly, the Reporting Persons intend to review the investment in the Company on a continuing basis and may engage in discussions with management, the Company’s Board of Directors, other shareholders of the Company and other relevant parties in order to enhance shareholder value. Such discussions aimed at enhancing shareholder value may concern, among other things, potential business combinations and strategic alternatives, and the business, operations, governance, management, strategy and future plans of the Company. Depending on various factors, including, without limitation, the outcome of any discussions reference above, the investment opportunities available to the Reporting Persons, conditions in the securities markets, and economic and industry conditions, the Reporting Persons may in the future take such actions with respect to the investment in the Company as the Reporting Persons deem appropriate.
    Except as set forth above, the Reporting Persons have no present plan or proposal that would relate to or result in any of the matters set forth in subparagraphs (a)-(j) of Item 4 of Schedule D.
    The Reporting Persons review their holdings in the Company on a continuing basis and as part of this ongoing review, evaluate various alternatives that are or may be available with respect to the securities of the Company. The Reporting Persons may from time to time and at any time, in their sole discretion, purchase additional equity or debt securities or other instruments of the Company or dispose of such equity or debt securities or other investments, in any amount that the Reporting Persons may determine in their sole discretion, through open market transactions, privately negotiated transactions or otherwise.
     
    ITEM 5. INTEREST IN SECURITIES OF THE ISSUER
     
     
    (a)
    The Reporting Persons beneficially own 4,250,000 Shares of the Company in the aggregate, representing approximately 5.90% of such class of securities. The percentage of the Shares beneficially owned by the Reporting Persons is based on a total of 72,038,439 Shares of the Company outstanding as of November 1, 2021, as reported in the Company's Form 10-Q for the quarterly period ended September 30, 2021 filed with the Securities and Exchange Commission on November 4, 2021
     
    (b)
    Camber has the power to dispose of and the power to vote the Shares beneficially owned by the Reporting Persons, which power may be exercised by its managing member, Mr. DuBois. By reason of the provisions of Rule 13d-3 of the Securities Exchange Act of 1934 (the "Act"), Mr. DuBois may be deemed to beneficially own the Shares held by the Reporting Persons.
     
     
    (c)
    None of the Reporting Persons nor, to the knowledge of the Reporting Persons, any person identified in response to Item 2, has effected any transactions in the Shares during the preceding 60 days
     
    (d)         Of the Shares reported herein, 4,221,726 Shares are held for the account of Camber Capital Master Fund, L.P.
    (e)         Not applicable.
     
    ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER
     
    Other than the Joint Filing Agreement attached as Exhibit 1 hereto, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the persons named in Item 2 hereof and between such persons and any person with respect to any securities of the Company, including but not limited to transfer or voting of any other securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, divisions of profits or loss, or the giving or withholding of proxies.
     
    ITEM 7. MATERIAL TO BE FILED AS EXHIBITS
    Exhibit 1:  Joint Filing Statement as required by Rule 13d(1)(k)(l) under the Act.

     
     
     
     
     
    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.
     
    Date: November 08, 2021
    Camber Capital Management LP
    By: /s/ Sean George
    Sean George
    Chief Financial Officer
     
                   Stephen DuBois
                   By: /s/ Stephen DuBois
    Stephen DuBois, individually
     
    Get the next $OSUR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OSUR

    DatePrice TargetRatingAnalyst
    1/3/2023$5.00In-line
    Evercore ISI
    2/24/2022$15.00 → $12.00Buy
    Citigroup
    9/22/2021Outperform → Market Perform
    Raymond James
    8/4/2021$11.00 → $12.50Outperform
    Raymond James
    6/28/2021$12.00 → $11.00Outperform
    Raymond James
    More analyst ratings

    $OSUR
    SEC Filings

    View All

    SEC Form DEFA14A filed by OraSure Technologies Inc.

    DEFA14A - ORASURE TECHNOLOGIES INC (0001116463) (Filer)

    3/17/26 5:29:43 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by OraSure Technologies Inc.

    10-K - ORASURE TECHNOLOGIES INC (0001116463) (Filer)

    3/9/26 4:29:14 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure Technologies Inc. filed SEC Form 8-K: Leadership Update

    8-K - ORASURE TECHNOLOGIES INC (0001116463) (Filer)

    3/5/26 4:15:16 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI resumed coverage on OraSure with a new price target

    Evercore ISI resumed coverage of OraSure with a rating of In-line and set a new price target of $5.00

    1/3/23 8:07:55 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    Citigroup reiterated coverage on OraSure Technologies with a new price target

    Citigroup reiterated coverage of OraSure Technologies with a rating of Buy and set a new price target of $12.00 from $15.00 previously

    2/24/22 8:34:18 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure Technologies downgraded by Raymond James

    Raymond James downgraded OraSure Technologies from Outperform to Market Perform

    9/22/21 5:02:16 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital

    Company Has Demonstrated Momentum on Transformation Strategy with Significant Regulatory and Commercial Milestones Approaching in 2026 Highlights Extensive Engagement with Altai Altai Has Rejected All Settlement Proposals and Is Singularly Focused on Securing Board Representation for Its Founder to Force an Ill-Timed Sale Process BETHLEHEM, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. ("OraSure" and the "Company") (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today issued the following statement in response to Altai Capital's March 17, 2026, letter: OraSure's Board and management team are steadfast in our commi

    3/17/26 4:52:45 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued Underperformance

    Calls on Company to Reach a Fair Settlement that Appoints Altai Nominees Rishi Bajaj and John Bertrand to the Board Altai Capital Management, L.P. ("Altai"), one of the largest shareholders and the beneficial owners of approximately 5% of the outstanding common stock of OraSure Technologies, Inc. ("OraSure" or the "Company") (NASDAQ:OSUR), today announced that it has delivered a letter to the OraSure Board of Directors (the "Board") outlining a five-pillar case for why change is necessary to preserve and deliver value for its investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317768148/en/ In the letter, Altai calls

    3/17/26 9:15:00 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure Announces Fourth Quarter 2025 Financial Results

    BETHLEHEM, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended December 31, 2025. "Our Q4 results were consistent with our expectations, and revenue of $26.8 million was above the midpoint of our guidance range," said Carrie Eglinton Manner, President and CEO of OTI. "We supported our customers in navigating a challenging funding environment in 2025, and we are encouraged to see increasing signs of stability in key segments as we enter 2026." She continued, "We are confident that OTI is positioned to return to g

    2/25/26 4:05:00 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Mcgrath Kenneth J bought $66,030 worth of shares (22,021 units at $3.00), increasing direct ownership by 4% to 557,262 units (SEC Form 4)

    4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    3/16/26 8:01:53 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    President & CEO Eglinton Manner Carrie bought $66,033 worth of shares (22,022 units at $3.00), increasing direct ownership by 1% to 2,158,574 units (SEC Form 4)

    4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    3/16/26 8:01:38 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    Director Gagliano Nancy J bought $4,982 worth of shares (2,100 units at $2.37), increasing direct ownership by 1% to 160,254 units (SEC Form 4)

    4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    12/2/25 4:16:00 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Anthony Michele Marie

    4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    3/19/26 4:05:45 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Mcgrath Kenneth J bought $66,030 worth of shares (22,021 units at $3.00), increasing direct ownership by 4% to 557,262 units (SEC Form 4)

    4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    3/16/26 8:01:53 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    President & CEO Eglinton Manner Carrie bought $66,033 worth of shares (22,022 units at $3.00), increasing direct ownership by 1% to 2,158,574 units (SEC Form 4)

    4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    3/16/26 8:01:38 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Leadership Updates

    Live Leadership Updates

    View All

    Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued Underperformance

    Calls on Company to Reach a Fair Settlement that Appoints Altai Nominees Rishi Bajaj and John Bertrand to the Board Altai Capital Management, L.P. ("Altai"), one of the largest shareholders and the beneficial owners of approximately 5% of the outstanding common stock of OraSure Technologies, Inc. ("OraSure" or the "Company") (NASDAQ:OSUR), today announced that it has delivered a letter to the OraSure Board of Directors (the "Board") outlining a five-pillar case for why change is necessary to preserve and deliver value for its investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317768148/en/ In the letter, Altai calls

    3/17/26 9:15:00 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure Technologies Appoints Steven K. Boyd to its Board of Directors

    Seasoned Investor with Deep Experience in the Healthcare and Medical Device Industries Brings Valuable Capital Markets Expertise and Investor Perspective  OraSure Board Has Added Three New Independent Directors in the Past Three Years Mara Aspinall to Step Down from the Board; Jack Kenny Appointed as Chair of the Board BETHLEHEM, Pa., Oct. 28, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. ("OTI") (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the appointment of Steven K. Boyd to its Board of Directors, as a Class II director, effective immediately. The addition of Mr. Boyd is part of OraSure's ongoing Board refr

    10/28/25 4:22:03 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure Appoints Anne Messing as Chief Commercial Officer

    BETHLEHEM, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. ("OTI") (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that Anne Messing has joined OTI as Chief Commercial Officer. Ms. Messing brings more than 25 years of commercial leadership experience across the healthcare industry, including in life sciences, diagnostics, and clinical laboratory services, with a proven track record of driving growth, building high-performing sales teams, and transforming strategic vision into demonstrable results and sustainable success. In her role at OTI, she will be responsible for Sales, Marketing, Strategic Alliance

    8/4/25 7:05:00 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Financials

    Live finance-specific insights

    View All

    OraSure Announces Fourth Quarter 2025 Financial Results

    BETHLEHEM, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended December 31, 2025. "Our Q4 results were consistent with our expectations, and revenue of $26.8 million was above the midpoint of our guidance range," said Carrie Eglinton Manner, President and CEO of OTI. "We supported our customers in navigating a challenging funding environment in 2025, and we are encouraged to see increasing signs of stability in key segments as we enter 2026." She continued, "We are confident that OTI is positioned to return to g

    2/25/26 4:05:00 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure to Announce Fourth Quarter 2025 Financial Results and Host Earnings Call on February 25th

    BETHLEHEM, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular earnings conference call covering fourth quarter 2025 financial results and certain business developments for 5 p.m. ET on February 25, 2026. A webcast of the conference call will be available on the investor relations page of OraSure's website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OraSure's website shortly after the call has ended. About OraSure Technologies, Inc. OraSure Technologies, Inc. ("OraSure"

    2/9/26 4:15:00 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure Announces Third Quarter 2025 Financial Results

    BETHLEHEM, Pa., Nov. 05, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended September 30, 2025. "In Q3 we delivered $27.1 million of revenue. While some of our customers continue to experience elevated levels of uncertainty related to funding for public health programs and research, we remain confident in our opportunities to return to growth in 2026, driven by diversification in our customer base and contributions from planned launches of new products in both rapid diagnostics and sample management solutions," said Carrie

    11/5/25 4:05:00 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by OraSure Technologies Inc.

    SC 13G/A - ORASURE TECHNOLOGIES INC (0001116463) (Subject)

    11/12/24 4:46:06 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by OraSure Technologies Inc.

    SC 13G/A - ORASURE TECHNOLOGIES INC (0001116463) (Subject)

    11/4/24 1:18:55 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by OraSure Technologies Inc.

    SC 13G - ORASURE TECHNOLOGIES INC (0001116463) (Subject)

    10/4/24 1:30:36 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care